Cocrystal Pharma, Inc. (18)

Browse by Contract Category

Contracts

Consulting and Scientific Advisory Board Agreement, dated April 13, 2021 with Roger Kornberg (Filed With SEC on August 16, 2021)
Underwriting Agreement, dated as of May 4, 2021 by and between Cocrystal Pharma, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on May 5, 2021)
License Agreement dated April 19, 2020, between the Company and Kansas State University Research Foundation (Filed With SEC on August 6, 2020)
At-The-Market Offering Agreement, dated July 1, 2020, by and between Cocrystal Pharma, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on July 2, 2020)
Placement Agency Agreement, dated as of January 29, 2020, by and between Cocrystal Pharma, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on January 31, 2020)
Amended and Restated Underwriting Agreement, dated as of August 26, 2020, by and between Cocrystal Pharma, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on August 27, 2020)
License Agreement, dated February 18, 2020, between the Company and Kansas State University Research Foundation (Filed With SEC on May 13, 2020)
Description of Capital Stock (Filed With SEC on March 27, 2020)
Form of Securities Purchase Agreement, dated March 9, 2020, by and between the Company and the Purchasers (Filed With SEC on March 13, 2020)
Engagement letter dated February 26, 2020 by and between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on March 4, 2020)
Form of Securities Purchase Agreement, dated February 27, 2020, by and between the Company and the Purchasers (Filed With SEC on March 4, 2020)
Form of Securities Purchase Agreement (Filed With SEC on January 31, 2020)
Amendment to the Amended and Restated Equity Distribution Agreement, dated October 2, 2019 (Filed With SEC on January 29, 2020)
Underwriting Agreement, dated as of October 30, 2019, by and between Cocrystal Pharma, Inc. and Aegis Capital Corp (Filed With SEC on October 31, 2019)
Amended and Restated Equity Distribution Agreement, dated October 30, 2019 (Filed With SEC on October 30, 2019)
Exclusive License and Research Collaboration Agreement between the Company and Merck Sharp & Dohme Corp., dated January 2, 2019 (Filed With SEC on April 1, 2019)
Amendment to Equity Distribution Agreement, dated March 20, 2019 (Filed With SEC on March 26, 2019)
Securities Purchase Agreement, dated March 11, 2019 (Filed With SEC on March 11, 2019)